SCHEMBL3759347

SCHEMBL3759347

O=C(O)c1ccn[c]c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
ALOX15 P16050 2/20 0.41
KDM4C Q9H3R0 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
KDM4A O75164 1/20 0.40
KDM5A P29375 1/20 0.40
HNF4A P41235 3/20 0.38
ACMSD Q8TDX5 3/20 0.38
DHFR P00374 1/20 0.38
MCL1 Q07820 1/20 0.38
CDC25B P30305 1/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
PDE10A Q9Y233 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
LDHA P00338 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761229 0.86 SMN1; SMN2 (0.40) ALDH1A1KDM4CKDM4ESMN1; SMN2HPGD
SCHEMBL3761415 0.86 BCAT2 (0.46) ALDH1A1KDM4EHPGDMAPTTSHR
SCHEMBL11452528 0.84 ALDH1A1 (0.44) ALDH1A1CDC25BATMKDM4ESMN1; SMN2
SCHEMBL3758759 0.82 KMT2A (0.50) ALDH1A1KDM4ESMN1; SMN2TDP1HPGD
SCHEMBL3769036 0.82 GAA (0.41) ALDH1A1KDM4EHPGDMAPTNPSR1
SCHEMBL3999416 0.80 NPC1 (0.36) ALDH1A1SMN1; SMN2LMNANPSR1NPC1
SCHEMBL3760380 0.78 TSHR (0.50) ALDH1A1KDM4ESMN1; SMN2LMNAHPGD
SCHEMBL3764668 0.78 HPGD (0.49) ALDH1A1LMNAHPGDMAPTTSHR
SCHEMBL3761439 0.78 TSHR (0.51) ALDH1A1ALOX15ATMKDM4ESMN1; SMN2
SCHEMBL3760647 0.78 TSHR (0.54) ALDH1A1KDM4ESMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885ALOX15 3714/4885KDM4C 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.